-20℃ 3 years powder
-80℃ 2 years in solvent
Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | 60.00 | |
5 mg | In stock | 110.00 | |
10 mg | In stock | 180.00 | |
25 mg | In stock | 360.00 | |
50 mg | In stock | 468.00 | |
1 mL * 10 mM (in DMSO) | In stock | 180.00 |
Description | Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. |
Targets&IC50 | GNRHR, |
Synonyms | TAK-385 , RVT-601 |
Purity | 98.64% |
Molecular Weight | 623.63 |
Formula | C29H27F2N7O5S |
CAS No. | 737789-87-6 |
-20℃ 3 years powder
-80℃ 2 years in solvent
DMSO: 55 mg/mL (88.2 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.